Immunotherapy

Immune checkpoint therapy, a type of cancer immunotherapy that helps the immune system recognize and attack tumors, has transformed cancer treatment.

Preventive house dust mite sublingual immunotherapy in sensitized, symptom-free preschoolers may safely induce blocking antibodies, reduce allergic responses, and limit new sensitizations.

Immunotherapies such as so-called checkpoint inhibitors activate the body's own immune system to fight cancer cells and have revolutionized the treatment of many types of tumor.

arXiv:2605.25050v1 Announce Type: new Abstract: Integrating multimodal datasets in clinical oncology is frequently hindered by high dimensionality and blockwise missingness, where entire data sources are unavailable for specific patient subsets. Standard survival models often struggle with these gaps, leading to biased results or patient exclusion. We introduce Multimodality Stacking with Blockwise missing values (MSB), a late-fusion framework for survival analysis that independently models modality-specific features before aggregating predictions via a cross-validated stacking meta-learner. MSB was validated on the PIONeeR study (n=443 patients, 378 biomarkers across eight heterogeneous sources) to predict progression-free survival in advanced non-small cell lung cancer patients receiving immunotherapy. MSB yielded higher predictive performance (C-index) than baseline algorithms. Improvements varied by baseline strength: linear models showed a 15.9% increase (p

arXiv:2605.25050v1 Announce Type: cross Abstract: Integrating multimodal datasets in clinical oncology is frequently hindered by high dimensionality and blockwise missingness, where entire data sources are unavailable for specific patient subsets. Standard survival models often struggle with these gaps, leading to biased results or patient exclusion. We introduce Multimodality Stacking with Blockwise missing values (MSB), a late-fusion framework for survival analysis that independently models modality-specific features before aggregating predictions via a cross-validated stacking meta-learner. MSB was validated on the PIONeeR study (n=443 patients, 378 biomarkers across eight heterogeneous sources) to predict progression-free survival in advanced non-small cell lung cancer patients receiving immunotherapy. MSB yielded higher predictive performance (C-index) than baseline algorithms. Improvements varied by baseline strength: linear models showed a 15.9% increase (p

arXiv:2605.25050v1 Announce Type: cross Abstract: Integrating multimodal datasets in clinical oncology is frequently hindered by high dimensionality and blockwise missingness, where entire data sources are unavailable for specific patient subsets. Standard survival models often struggle with these gaps, leading to biased results or patient exclusion. We introduce Multimodality Stacking with Blockwise missing values (MSB), a late-fusion framework for survival analysis that independently models modality-specific features before aggregating predictions via a cross-validated stacking meta-learner. MSB was validated on the PIONeeR study (n=443 patients, 378 biomarkers across eight heterogeneous sources) to predict progression-free survival in advanced non-small cell lung cancer patients receiving immunotherapy. MSB yielded higher predictive performance (C-index) than baseline algorithms. Improvements varied by baseline strength: linear models showed a 15.9% increase (p

Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.

Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

Immunotherapy could be used to treat depression, early trial suggests  The GuardianPilot trial suggests anti-inflammatory drug could help difficult-to-treat depression  Medical XpressExperts uncover anti-inflammatory drug that could help millions of Brits who suffer from depression  The IndependentDepression ‘cured’ in half of patients taking arthritis drug given to thousands  The SunAnti-Inflammatory Drug Could Help Some People with Depression  Inside Precision Medicine

Immunotherapy could be used to treat depression, early trial suggests  The GuardianPilot trial suggests anti-inflammatory drug could help difficult-to-treat depression  Medical XpressExperts uncover anti-inflammatory drug that could help millions of Brits who suffer from depression  The IndependentDepression ‘cured’ in half of patients taking arthritis drug given to thousands  The SunAnti-Inflammatory Drug Could Help Some People with Depression  Inside Precision Medicine

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types of rare cancers are likely to respond to immunotherapy.

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual cancer cells die, exposing their internal scaffolds.

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

Researchers at the Francis Crick Institute have revealed that sensory nerve signals interfere with the immune system's response to lung cancer.

NICE has recommended durvalumab for NHS use in England as part of perioperative treatment for adults with resectable gastric or gastro-oesophageal junction adenocarcinoma.

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit. Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade (ICB).

Engineered nanoparticles can improve cancer immunotherapy by delivering drugs, antigens, and genetic payloads with greater precision while remodeling the tumor microenvironment. The review highlights how nano-immunotherapy could boost immune activation, improve checkpoint-blockade responses, and support more personalized cancer treatment, although safety, scalability, and clinical translation challenges remain.

A Swedish randomized trial found that slow up-dosing peanut oral immunotherapy with a low maintenance dose helped 82% of preschool children achieve sustained peanut tolerance after three years. The approach proved safer than conventional protocols, with severe reactions uncommon and strong family adherence throughout treatment.

In this webinar, Joseph Shultz (VP of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (VP of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. The post From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies appeared first on GEN - Genetic Engineering and Biotechnology News.

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer, one of the leading causes of cancer-related deaths worldwide.

Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy  Fox NewsBreakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years  SciTechDailyPre-Surgery Immunotherapy Shows Promising Results in Bowel Cancer  The Indian PractitionerImmunotherapy Trial Shows 100 Percent Success Rate for Bowel Cancer Patients  HarianBasis.co

Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy  Fox NewsBreakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years  SciTechDailyPre-Surgery Immunotherapy Shows Promising Results in Bowel Cancer  The Indian PractitionerImmunotherapy Trial Shows 100 Percent Success Rate for Bowel Cancer Patients  HarianBasis.co

arXiv:2604.24360v1 Announce Type: new Abstract: Immune checkpoint inhibitor--based therapies often produce heterogeneous survival responses, including early risk, delayed treatment benefit, and durable long-term survival in a subset of patients. In these settings, conventional summary measures such as the hazard ratio may not adequately describe how treatment effects evolve over follow-up. We propose a milestone-based framework that separates long-term survival beyond a clinically meaningful time point from earlier outcomes and provides a practical way to characterize patient heterogeneity in treatment response. The framework summarizes treatment differences through milestone survival probabilities and, among patients who do not reach the milestone, characterizes short-term treatment ordering over time using a tau-based summary that helps identify hazard reversal. We illustrate the approach using reconstructed individual-level data from three landmark phase III trials: CheckMate~067,

A small Italian study suggests a way to safely reduce gastrectomy rates in microsatellite instability-high disease.

In the context of Alzheimer's disease, the data for anti-amyloid immunotherapies, the most recent of which do effectively clear the aggregation of amyloid-β in the brain, is not compelling. Clinical trials and following studies show minimal to no benefit to patients even at earlier stages of the condition. There is some hope in the research and development community, where the amyloid cascade hypothesis remains dominant, that moving to even earlier deployment of these therapies might prevent the emergence of the condition, but the data obtained to date does not inspire optimism on this front. Other directions are much needed, perhaps restoration of cerebrospinal fluid drainage, for example, or more of a focus on chronic inflammation in brain tissue. Alzheimer's disease is a neurodegenerative disorder and […]

Omalizumab, alone or with allergen immunotherapy for house dust mites, may reduce daily use of inhaled corticosteroids in patients with house dust mite-sensitized mild-to-moderate allergic asthma.

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.

A new UCLA Health Jonsson Comprehensive Cancer Center study suggests that the way immune cells are organized inside melanoma tumors may help researchers better understand which patients will benefit from combination immunotherapy after standard anti-PD-1 treatment stops working - and which may not.

An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small cell lung cancer (NSCLC).

Path-IO accurately stratified immunotherapy outcomes for patients with metastatic non-small cell lung cancer (NSCLC). The model is validated across international real-world cohorts and a Phase III randomized clinical trial. The post AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model appeared first on GEN - Genetic Engineering and Biotechnology News.

Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in patients who experienced co-occurring myositis and myasthenia gravis, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

Patients with a specific type of bowel cancer who were treated with a short course of immunotherapy before surgery instead of post-op chemotherapy have remained cancer-free after almost three years of follow-up, according to new results from the NEOPRISM-CRC clinical trial led by a team from UCL and UCLH.

A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

A phase 2 study evaluates the safety and efficacy of brentuximab vedotin and nivolumab plus chemotherapy in patients with early-stage classical Hodgkin lymphoma.

SUNDAY, April 19, 2026 — Immunotherapy has largely failed as a treatment for cancer of the pancreas, and researchers have zeroed in on a key reason.Pancreatic tumors reprogram immune cells that normally shut down tumor-killing cells, according to a...

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide.

The Scottish Medicines Consortium has accepted pembrolizumab with chemoradiotherapy for high-risk, locally advanced cervical cancer in Scotland.

'It's incredible, like science fiction': How a new wave of immunotherapy is eliminating cancers  BBC

'It's incredible, like science fiction': How a new wave of immunotherapy is eliminating cancers  BBC

Macrophages, much like Alice of "Alice in Wonderland," recognize and consume tumor cells that display "eat me" surface markers.

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer - and identified a promising strategy to overcome that resistance.

A UAB research team defines the criteria that CAR immunotherapies for neurodegenerative diseases must meet to advance both conceptually and in trials, which are still at a very preliminary stage, in a review study published in the journal Trends in Pharmacological Sciences.

arXiv:2604.05478v1 Announce Type: new Abstract: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal

arXiv:2604.05478v1 Announce Type: cross Abstract: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only

A new tool makes it possible to screen millions of tiny protein fragments and select those that can be recognized by the immune system. The CIC biomaGUNE Center for Cooperative Research in Biomaterials has developed epiGPTope, a system that uses machine learning to generate and classify epitopes, in collaboration with the company Multiverse Computing.

A new metabolic mechanism describes how tumors disable immune “gatekeeper” in the presence of cancer. Study shows that boosting mitochondrial function in dendritic cells enhances antitumor immune activity and strengthens the efficacy immunotherapies. The post Immunotherapy Enhanced by Restoring Mitochondrial Function in Dendritic Cells appeared first on GEN - Genetic Engineering and Biotechnology News.

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer - and how restoring their energy production can improve immunotherapy. Dendritic cells activate the cytotoxic immune cells that destroy cancer.

Researchers developed novel, first-in-class drugs that inhibit both HIF-1 and HIF-2 and which, combined with immunotherapy, eliminated breast, colorectal, melanoma, and prostate tumors in mice, suggesting that the drugs could eventually be used to treat a broad range of cancers in humans. The post Combining Novel Dual HIF Inhibitors with Immunotherapy Erases Multiple Tumor Types in Mice appeared first on GEN - Genetic Engineering and Biotechnology News.

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression.

Immune-related pruritus may be observed in a quarter of patients with metastatic melanoma treated with immune checkpoint inhibitors.

arXiv:2604.00739v1 Announce Type: new Abstract: Datasets used in immunotherapy response prediction are typically small in size, as well as diverse in cancer type, drug administered, and sequencer used. Models often drop in performance when tested on patient cohorts that are not included in the training process. Recent work has shown that transformer-based models along with self-supervised learning show better generalisation performance than threshold-based biomarkers, but is still suboptimal. We present BioCOMPASS, an extension of a transformer-based model called COMPASS, that integrates biomarkers and treatment information to further improve its generalisability. Instead of feeding biomarker data as input, we built loss components to align them with the model's intermediate representations. We found that components such as treatment gating and pathway consistency loss improved generalisability when evaluated with Leave-one-cohort-out, Leave-one-cancer-type-out and

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called

Advanced gastric cancer remains one of the deadliest malignancies, with a 5-year overall survival rate below 10%.

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.

A new approach engineers immune cells to recognize byproducts of cancer cells to trigger migration toward solid tumors.The method differs from CAR T-cell therapy, which recognizes proteins tethered to the surface of the cancer cell.   The post Immunotherapy for Solid Tumors Enhanced by Metabolite-Sensing Receptors appeared first on GEN - Genetic Engineering and Biotechnology News.

Thymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThymic health consequences in adults  NatureLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical XpressThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanClinical briefs for Thursday, March 19  McKnight's Long-Term Care News

Thymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThymic health consequences in adults  NatureLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical XpressThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanClinical briefs for Thursday, March 19  McKnight's Long-Term Care News

Thymic health and immunotherapy outcomes in patients with cancer  NatureThymic health consequences in adults  NatureThymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical Xpress

Thymic health and immunotherapy outcomes in patients with cancer  NatureThymic health consequences in adults  NatureThymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical Xpress

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well to immunotherapy.

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including common variants such as cancers of the breast, liver, and colon.

Northwestern Medicine scientists have discovered that specialized immune cells within the glioblastoma tumor metabolize fructose to suppress immune responses and promote tumor growth, reports a study published on March 17 in the Proceedings of the National Academy of Sciences.

The collaboration’s first public sign of trouble came in the first quarter of 2025, when Astellas opted not to continue IND enabling activities it had initiated for the companies’ first collaboration target—choosing instead to prioritize their second nominated collaboration target by initiating GLP toxicology studies for the molecule. The post Astellas Scraps Up-to-$1.7B CytomX Cancer Immunotherapy Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News.

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology.

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous tumors.

A Common Drug May Make Cancer Immunotherapy Work Better  SciTechDailyMedication Interactions in Immunotherapy With Dr. Arabella Young: PPIs and ICI Toxicity  Docwire News

A Common Drug May Make Cancer Immunotherapy Work Better  SciTechDailyMedication Interactions in Immunotherapy With Dr. Arabella Young: PPIs and ICI Toxicity  Docwire News

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

arXiv:2602.23488v1 Announce Type: new Abstract: We continue our study of a model for cancer treatment, constructed in Dutta et. al., 2025, by adding Virotherapy to the Chemotherapy and Immunotherapy studied there. It is a dynamical system model for the spread of cancer in healthy tissue. It allows computer experiments of various combinations of the three modalities, which cannot be performed in the laboratory or experimentally. The novelty is the addition of Virotherapy. The analysis shows that the model solutions exist, are bounded, and nonnegative on each finite time interval, thus biologically feasible. A time-stepping algorithm is constructed and implemented, and computer simulations are presented. The simulations show the development of the disease under various treatment options, including a baseline case without treatment, cases for each of the three treatments separately, and some combinations of the three treatments. These simulations indicate that combinations of treatments

Ultrasound-mediated nanobubbles improve cancer therapy by softening tumors, enhancing lipid nanoparticle distribution, and activating immune responses.

Researchers developed a CAR T technology, called DROP-CAR, that incorporates human protein components, and uses a clinically approved, non-immunosuppressive drug to remotely and reversibly switch off the CAR T cells by disrupting tumor cell binding. The post Drug-Controlled CAR T Cells May Enable Safer Immunotherapy appeared first on GEN - Genetic Engineering and Biotechnology News.

A study found that a protein made by stressed cancer cells shields lung and pancreatic tumors in mice from the immune system, and showed that an antibody targeting lipocalin 2 slowed cancer growth in mice by enabling the immune system to target tumor cells. The post Cancer Immunotherapy Improved Using Targeted Stress Protein appeared first on GEN - Genetic Engineering and Biotechnology News.

Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment.

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

A small team at OVACell is fighting ovarian cancer with hidden viral sequences and advanced immunotherapies.

A cohort study examines whether the use of common medications was associated with worse outcomes in patients with lung cancer taking immunotherapy.

Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.

Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster, benefiting patients.

Initiating cow’s milk oral immunotherapy earlier in life is safe and linked to lower reactogenicity and a milder immunologic profile.

A new study offers hope that kidney transplant patients could one day have a monthly treatment instead of multiple pills every day.

European regulators have endorsed Imfinzi as part of a perioperative treatment strategy that significantly reduces recurrence and death in early-stage gastric and gastroesophageal junction cancer.

Blocking microglial Fcγ receptors can prevent dopaminergic neuron loss in Parkinson’s disease, shows a new study. The findings reveal how microglia drive degeneration and point to immunotherapy as a potential neuroprotective strategy. The post Immunotherapy Blocking Microglial FcγR Prevents Neuron Loss in Parkinson’s Disease appeared first on GEN - Genetic Engineering and Biotechnology News.

By analyzing tissue from patients with Parkinson's disease, and animal and cellular models of the disease, a research team from the Institut de Neurociències of the UAB has shown that the main immune cells of the brain become reactive and overexpress certain receptors that promote the elimination of dopaminergic neurons, even when these neurons are still functional.

FRIDAY, Jan. 30, 2026 — An already-approved immunotherapy drug can dramatically shrink — or even eliminate — tumors associated with a rare and aggressive form of melanoma, a new clinical trial has found. About 71% of desmoplastic...

It is the first immunotherapy-based treatment recommended in Europe for advanced anal cancer.

FRIDAY, Jan. 30, 2026 — An already-approved immunotherapy drug can dramatically shrink — or even eliminate — tumors associated with a rare and aggressive form of melanoma, a new clinical trial has found.About 71% of desmoplastic melanoma patients tr...

Scientists designed an immunotherapy using an engineered antibody to destroy harmful modulated smooth muscle cells located within blood vessel walls that plays a central role in driving inflammation and plaque formation in heart arteries. The post Immunotherapy Reduces Plaque in Mouse Arteries, Suggesting Coronary Disease Intervention appeared first on GEN - Genetic Engineering and Biotechnology News.

New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and aggressive skin cancer, with immunotherapy before surgery can dramatically shrink or even eliminate tumors, sparing patients from more aggressive surgeries and preserving their quality of life.

Fecal microbiota transplants (FMT), can dramatically improve cancer treatment, suggest two groundbreaking studies published in the prestigious Nature Medicine journal.

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research reveals a hidden trick: cancer cells can package the immune-blocking protein PD-L1 into tiny particles that circulate through the body and weaken immunotherapy’s impact. Scientists in Japan discovered that a little-known protein, UBL3, controls this process—and surprisingly, common cholesterol-lowering drugs called statins can shut it down.